Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) is a rare disease caused by mutations to the UNC13D gene and the subsequent absence or decreased activity of the Munc13-4 protein. Munc13-4 is essential for the exocytosis of perforin and granzyme containing granules from cytotoxic cells. Without it, these cells are able to recognize an immunological insult but are unable to execute their cytotoxic functions. The result is a hyperinflammatory state that, if left untreated, is fatal. At present, the only curative treatment is hematopoietic stem cell transplantation (HSCT), but eligibility and response to this treatment are largely dependent on the ability to control inflammation before HSCT. In this study, we describe an optimized lentiviral vector that can restore Munc13-4 expression and degranulation capacity in both transduced FHL3 patient T cells and transduced hematopoietic stem cells from the FHL3 (Jinx) disease model.
Get full access to this article
View all access options for this article.
References
1.
HenterJI, ElinderG, OstA. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol, 1991; 18:29–33.
2.
HenterJI, HorneA, AricoM, et al.HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 2007; 48:124–131.
3.
DasR, BarN, FerreiraM, et al.Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest, 2018; 128:715–720.
4.
FilipovichAH.Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program, 2009:127–131.
5.
VickEJ, PatelK, ProuetP, et al.Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy. Blood Adv, 2017; 1:779–791.
6.
EifeR, JankaGE, BelohradskyBH, et al.Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol, 1989; 6:265–272.
7.
KimT, KulickCG, KortepeterCM, et al.Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine. Neurology, 2019; 92:e2401–e2405.
8.
FeldmannJ, CallebautI, RaposoG, et al.Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell, 2003; 115:461–473.
9.
HenterJI, Samuelsson-HorneA, AricoM, et al.Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood, 2002; 100:2367–2373.
10.
Ouachee-ChardinM, ElieC, de Saint BasileG, et al.Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics, 2006; 117:e743–e750.
11.
BakerKS, DeLaatCA, SteinbuchM, et al.Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood, 1997; 89:3857–3863.
12.
HorneA, JankaG, Maarten EgelerR, et al.Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol, 2005; 129:622–630.
13.
ImashukuS, HibiS, TodoS, et al.Allogenic hematopoietic stem cell transplanation for patients with hemophagocytic syndrome (HPS) in Japan. Bone Marrow Transplant, 1999; 23:569–572.
14.
CesaroS, LocatelliF, LaninoE, et al.Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica, 2008; 93:1694–1701.
15.
DurkenM, HorstmannM, BielingP, et al.Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients. Br J Haematol, 1999; 106:1052–1058.
16.
CooperN, RaoK, GilmourK, et al.Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood, 2006; 107:1233–1236.
17.
CooperN, RaoK, GouldenN, et al.The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant, 2008; 42(Suppl 2):S47–S50.
18.
BergstenE, HorneA, AricoM, et al.Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long term results of the cooperative HLH-2004 study. Blood, 2017; 130:2728–2738.
19.
MalinowskaI, MachaczkaM, PopkoK, et al.Hemophagocytic syndrome in children and adults. Arch Immunol Ther Exp (Warsz), 2014; 62:385–394.
20.
AllenCE, MarshR, DawsonP, et al.Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood, 2018; 132:1438–1451.
21.
TrottestamH, HorneA, AricoM, et al.Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood, 2011; 118:4577–4584.
22.
DettmerV, BloomK, GrossM, et al.Retroviral UNC13D gene transfer restores cytotoxic activity of T cells derived from familial hemophagocytic lymphohistiocytosis type 3 patients in vitro. Hum Gene Ther, 2019; 30:975–984.
23.
SoheiliT, DurandA, SepulvedaFE, et al.Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency. Blood Adv, 2017; 1:2781–2789.
24.
SoheiliT, RiviereJ, RicciardelliI, et al.Gene-corrected human Munc13-4-deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice. Blood, 2016; 128:2859–2862.
25.
AmmannS, LehmbergK, Zur StadtU, et al.Effective immunological guidance of genetic analyses including exome sequencing in patients evaluated for hemophagocytic lymphohistiocytosis. J Clin Immunol, 2017; 37:770–780.
26.
JordanMB, AllenCE, WeitzmanS, et al.How I treat hemophagocytic lymphohistiocytosis. Blood, 2011; 118:4041–4052.
27.
MeethsM, ChiangSC, WoodSM, et al.Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood, 2011; 118:5783–5793.
28.
SeoJY, SongJS, LeeKO, et al.Founder effects in two predominant intronic mutations of UNC13D, c.118-308C>T and c.754-1G>C underlie the unusual predominance of type 3 familial hemophagocytic lymphohistiocytosis (FHL3) in Korea. Ann Hematol, 2013; 92:357–364.
29.
ElstakED, te LooM, TesselaarK, et al.A novel Dutch mutation in UNC13D reveals an essential role of the C2B domain in munc13-4 function. Pediatr Blood Cancer, 2012; 58:598–605.
30.
ChenZ, CooperB, KallaS, et al.The Munc13 proteins differentially regulate readily releasable pool dynamics and calcium-dependent recovery at a central synapse. J Neurosci, 2013; 33:8336–8351.
31.
Zur StadtU, BeutelK, KolbergS, et al.Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat, 2006; 27:62–68.
32.
EntesarianM, ChiangSC, SchlumsH, et al.Novel deep intronic and missense UNC13D mutations in familial haemophagocytic lymphohistiocytosis type 3. Br J Haematol, 2013; 162:415–418.
33.
BinNR, MaK, TienCW, et al.C2 domains of Munc13-4 are crucial for Ca(2+)-dependent degranulation and cytotoxicity in NK cells. J Immunol, 2018; 201:700–713.
34.
Pivot-PajotC, VaroqueauxF, de Saint BasileG, et al.Munc13-4 regulates granule secretion in human neutrophils. J Immunol, 2008; 180:6786–6797.
35.
XuR, ZhouJ, ZhouXD, et al.Munc134 mediates human neutrophil elastaseinduced airway mucin5AC hypersecretion by interacting with syntaxin2. Mol Med Rep, 2018; 18:1015–1024.
36.
CardenasEI, BreauxK, DaQ, et al.Platelet Munc13-4 regulates hemostasis, thrombosis and airway inflammation. Haematologica, 2018; 103:1235–1244.
37.
RodarteEM, RamosMA, DavalosAJ, et al.Munc13 proteins control regulated exocytosis in mast cells. J Biol Chem, 2018; 293:345–358.
38.
JankaGE.Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med, 2012; 63:233–246.
39.
GiardinoG, De LucaM, CirilloE, et al.Two brothers with atypical UNC13D-related hemophagocytic lymphohistiocytosis characterized by massive lung and brain involvement. Front Immunol, 2017; 8:1892.
40.
ChehabT, SantosNC, HolthenrichA, et al.A novel Munc13-4/S100A10/annexin A2 complex promotes Weibel-Palade body exocytosis in endothelial cells. Mol Biol Cell, 2017; 28:1688–1700.
41.
GaoJ, AksoyBA, DogrusozU, et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 2013; 6:pl1.
42.
MessengerSW, WooSS, SunZ, et al.A Ca(2+)-stimulated exosome release pathway in cancer cells is regulated by Munc13-4. J Cell Biol, 2018; 217:2877–2890.
43.
BrownHC, ZakasPM, GeorgeSN, et al.Target-cell-directed bioengineering approaches for gene therapy of hemophilia A. Mol Ther Methods Clin Dev, 2018; 9:57–69.
44.
JohnstonJM, DenningG, DoeringCB, et al.Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A. Gene Ther, 2013; 20:607–615.
45.
NiD, XuP, GallagherS.Immunoblotting and immunodetection. Curr Protoc Protein Sci, 2017; 88:10.10.1–10.10.37
46.
WegehauptAK, RoufsEK, HewittCR, et al.Recovery and assessment of leukocytes from LR Express filters. Biologicals, 2017; 49:15–22.
47.
NeronS, DussaultN, RacineC. Whole-blood leukoreduction filters are a source for cryopreserved cells for phenotypic and functional investigations on peripheral blood lymphocytes. Transfusion, 2006; 46:537–544.
48.
ChallitaPM, SkeltonD, el-KhoueiryA, et al.Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol, 1995; 69:748–755.
49.
KozakM.Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 1986; 44:283–292.
50.
BrownHC. Bioengineering viral transgenes for the treatment of hemophilias. Doctoral dissertation, Molecular and Systems Pharmacology. Emory University, 2016. https://etd.library.emory.edu/concern/etds/2z10wq65r?locale=en (last accessed June6, 2020).
51.
ChenY, MillerWM, AiyarA. Transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio. Biotechnol Prog, 2005; 21:274–282.
52.
SantilliG, AlmarzaE, BrendelC, et al.Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther, 2011; 19:122–132.
53.
BrendelC, RotheM, SantilliG, et al.Non-clinical efficacy and safety studies on G1XCGD, a lentiviral vector for ex vivo gene therapy of X-linked chronic granulomatous disease. Hum Gene Ther Clin Dev, 2018; 29:69–79.
54.
OzogS, ChenCX, SimpsonE, et al.CD46 null packaging cell line improves measles lentiviral vector production and gene delivery to hematopoietic stem and progenitor cells. Mol Ther Methods Clin Dev, 2019; 13:27–39.
55.
TakeuchiK, MiyajimaN, NagataN, et al.Wild-type measles virus induces large syncytium formation in primary human small airway epithelial cells by a SLAM(CD150)-independent mechanism. Virus Res, 2003; 94:11–16.
56.
DelvilleM, SoheiliT, BellierF, et al.A nontoxic transduction enhancer enables highly efficient lentiviral transduction of primary murine T cells and hematopoietic stem cells. Mol Ther Methods Clin Dev, 2018; 10:341–347.
57.
LevyC, AmiracheF, CostaC, et al.Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells. Mol Ther, 2012; 20:1699–1712.
58.
JohnstonJM, DenningG, MootR, et al.High-throughput screening identifies compounds that enhance lentiviral transduction. Gene Ther, 2014; 21:1008–1020.
59.
CrozatK, HoebeK, UgoliniS, et al.Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J Exp Med, 2007; 204:853–863.
60.
TerrellCE, JordanMB. Mixed hematopoietic or T-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood, 2013; 122:2618–2621.
61.
TranR, MyersDR, DenningG, et al.Microfluidic transduction harnesses mass transport principles to enhance gene transfer efficiency. Mol Ther, 2017; 25:2372–2382.
62.
SeoJJ.Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: recent advances and controversies. Blood Res, 2015; 50:131–139.
63.
CarmoM, RismaKA, ArumugamP, et al.Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency. Mol Ther, 2015; 23:737–745.
64.
Tayebeh-Shabi SoheiliIR, RiviereJ, DurandA, et al.Correction of CTLs cytotoxic function defect by SIN-lentiviral mediated expression of Munc13-4 in type 3 familial hemophagocytic lymphohistiocytosiss. American Society of Gene and Cell Therapy Meeting Abstracts, 2016; 24:S270.
65.
HartzB, MarshR, RaoK, et al.The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood, 2016; 127:3281–3290.
66.
GhoshS, CarmoM, Calero-GarciaM, et al.T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations. J Allergy Clin Immunol, 2018; 142:904.e3–913.e3.
67.
MarcenaroS, GalloF, MartiniS, et al.Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood, 2006; 108:2316–2323.
68.
KrebsP, CrozatK, PopkinD, et al.Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood, 2011; 117:6582–6588.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
